Paid Clinical Trials for Advanced Malignant Solid Neoplasm

Showing 21 – 40 of 41 results

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

in Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma

Other

California

Deadline:

04/10/2026

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

by CTG

in Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Recurrent Melanoma

Other

New Jersey

Deadline:

09/17/2026

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

by CTG

in Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A

Other

New York

Deadline:

04/01/2027

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

by CTG

in Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Refractory Brain Neoplasm

Other

Texas

Deadline:

10/31/2027

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH – Subprotocol Z1L)

by CTG

in Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

Other

Pennsylvania

Deadline:

12/31/2026

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

by CTG

in Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Stage III Pancreatic Cancer AJCC v8, Refractory Pancreatic Adenocarcinoma

Other

California

Deadline:

02/07/2030

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

by CTG

in Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm

Other

Pennsylvania

Deadline:

12/31/2026

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

by CTG

in Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Malignant Solid Neoplasm

Other

Texas

Deadline:

04/30/2026

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

by CTG

in Stage III Lung Cancer AJCC v8, Advanced Malignant Solid Neoplasm, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Extensive Stage Lung Small Cell Carcinoma

Other

California

Deadline:

01/03/2027

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

by CTG

in Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8

Other

Alabama

Deadline:

07/01/2030

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

by CTG

in Advanced Malignant Solid Neoplasm

Other

Massachusetts

Deadline:

08/02/2026

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH – Subprotocol L)

by CTG

in Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

Other

Pennsylvania

Deadline:

12/31/2026

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

by CTG

in Breast Carcinoma, Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Cervical Carcinoma, Bladder Carcinoma

Other

Alabama

Deadline:

12/31/2026

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

by CTG

in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm

Other

California

Deadline:

03/31/2028

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

by CTG

in Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm

Other

Texas

Deadline:

06/03/2026

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

by CTG

in Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm

Other

Texas

Deadline:

12/31/2026

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

by CTG

in Advanced Malignant Solid Neoplasm

Other

Florida

Deadline:

03/15/2027

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH – Subprotocol M)

by CTG

in Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

Other

Pennsylvania

Deadline:

12/31/2026

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

by CTG

in Glioblastoma, Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Glioma, Recurrent Cholangiocarcinoma

Other

California

Deadline:

07/28/2026

Patient Considerations of Social Media Account Management After Death

by CTG

in Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm

Other

Texas

Deadline:

12/31/2026

Load more All clinical trials loaded.

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH – Subprotocol Z1L)

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH – Subprotocol L)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH – Subprotocol M)

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Patient Considerations of Social Media Account Management After Death

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Advanced Malignant Solid Neoplasm

Filter Results:

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps